Menu

Biosimilars

Patent 2 V13E31

Amgen sues Sandoz over etanercept biosimilar

Biosimilars/General | Posted 11/03/2016

Following the submission of application for approval of its etanercept biosimilar in the US, Sandoz is coming under fire from originator company Amgen.

picture08

Epirus starts phase III trial for infliximab biosimilar

Biosimilars/News | Posted 11/03/2016

US-based biologicals company Epirus Biopharmaceuticals (Epirus) announced on 9 February 2016 that it had started a phase III trial for its infliximab biosimilar (BOW015).

138 AA011155

Beyond biosimilarity

Biosimilars/Research | Posted 04/03/2016

The advent of monoclonal antibody (mAb) biosimilars has raised a series of questions in the healthcare community. Just a few of these questions were discussed by Professor Pierre Michetti, a gastroenterologist at the Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland [1]. 

Acquisition Fall Off V13F07

Sandoz acquires EEA rights to infliximab biosimilar from Pfizer

Biosimilars/General | Posted 04/03/2016

Sandoz, the generics division of Novartis, announced on 12 February 2016 that it had acquired the rights for the development and commercialization of Pfizer’s biosimilar infliximab (PF-06438179) in the European Economic Area (EEA), which includes the 28 countries of the European Union (EU), plus Iceland, Liechtenstein and Norway.

Educate Yourself V13H02

FDA releases ‘Overview of Biosimilar Products’

Biosimilars/General | Posted 26/02/2016

As part of its ongoing mission to educate industry, the public and healthcare professionals about biosimilars, the US Food and Drug Administration (FDA) has released an online educational course for healthcare professionals.

Approved-V13G05

Trastuzumab non-originator biological approved in Russia

Biosimilars/News | Posted 26/02/2016

Russian biotechnology company Biocad announced on 20 January 2016 that the Russian Ministry of Health had approved the company’s trastuzumab non-originator biological, BCD-022. The drug is a non-originator biological of Roche’s breast cancer blockbuster Herceptin (trastuzumab).

Efficacy, Extrapolation, Interchangeability V16E25LB

Efficacy and safety of biosimilar infliximab compared to other biologicals in rheumatoid arthritis

Biosimilars/Research | Posted 26/02/2016

In the paper by Baji et al. [1], the authors carried out a meta-analysis to compare the efficacy and safety of biosimilar infliximab and other available biologicals for the treatment of rheumatoid arthritis (RA), namely abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab and tocilizumab. The analysis compared the recommended doses of biological disease-modifying anti-rheumatic drugs (DMARDs) indicated in RA.

Clinical Trials 2 V13K29

Safety concerns limit similar biologics uptake in India

Biosimilars/Research | Posted 26/02/2016

How do concerns about the safety of domestic biologicals limit the uptake of ‘similar biologics’ in India? This is a question that author Malipatil tried to address in his review of similar biologics in India [1].

Biological 143606710 V14J14ct

Differences between biosimilars and reference products

Biosimilars/Research | Posted 19/02/2016

A review of glycosylated biosimilars approved in the European Union (EU) and Japan has highlighted structural variances between biosimilars and their reference products [1].

Review committee V15a16

FDA advisers recommend approval of Celltrion’s infliximab biosimilar

Biosimilars/News | Posted 19/02/2016

US Food and Drug Administration’s (FDA) advisers have voted to recommend the approval of Celltrion’s biosimilar version of Johnson & Johnson and Merck’s arthritis treatment Remicade (infliximab).